Correction: Heterochromatin protein HP1g promotes colorectal cancer progression and is regulated by miR-30a (Cancer Research (2015) 75 (4593-4604) DOI: 10.1158/0008-5472.CAN-14-3735);Heterochromatin protein HP1g promotes colorectal cancer progression and is regulated by MIR-30a

Cancer Research

Volumn 75, Issue 21, 2015, Pages 4593-4604

  Liu, Ming ^a   Huang, Feifei ^a   Zhang, Dan ^b   Ju, Junyi ^a   Wu, Xiao Bin ^b   Wang, Ying ^a   Wang, Yadong ^a   Wu, Yupeng ^a   Nie, Min ^a   Li, Zhuchen ^a   Ma, Chi ^a   Chen, Xi ^a   Zhou, Jin Yong ^b   Tan, Renxiang ^a   Yang, Bo Lin ^b   Zen, Ke ^a   Zhang, Chen Yu ^a   Chen, Yu Gen ^b   Zhao, Quan ^a  

^a NANJING UNIVERSITY   (China)

^b AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; HETEROCHROMATIN PROTEIN 1; MICRORNA; MICRORNA 30A; PROTEIN P21; UNCLASSIFIED DRUG; CBX3 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; HISTONE; MIRN30 MICRORNA, HUMAN; NONHISTONE PROTEIN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; HISTONE METHYLATION; HP1GAMMA GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL TRANSFORMATION; COLORECTAL TUMOR; DISEASE COURSE; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; HCT116 CELL LINE; HEK293 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL PROTEINS, NON-HISTONE; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; DNA METHYLATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HEK293 CELLS; HISTONES; HUMANS; MICE; MICE, NUDE; MICRORNAS; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS;

EID: 84946599684     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-18-1309     Document Type: Erratum

References (42)

1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-907.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
3. Eissenberg JC, James TC, Foster-Hartnett DM, Hartnett T, Ngan V, Elgin SC. Mutation in a heterochromatin-specific chromosomal protein is associated with suppression of position-effect variegation in Drosophila melanogaster. Proc Natl Acad Sci U S A 1990;87:9923-7.
4. Lachner M, O'Carroll D, Rea S, Mechtler K, Jenuwein T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 2001; 410:116-20.
5. Bannister AJ, Zegerman P, Partridge JF, Miska EA, Thomas JO, Allshire RC, et al. Selective recognition ofmethylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 2001;410:120-4.
6. Canzio D, Larson A, Narlikar GJ.Mechanisms of functional promiscuity by HP1 proteins. Trends Cell Biol 2014;24:377-86.
7. Minc E, Courvalin JC, Buendia B. HP1gamma associates with euchromatin and heterochromatin inmammalian nuclei and chromosomes. Cytogenet Cell Genet 2000;90:279-84.
8. Nielsen SJ, Schneider R, Bauer UM, Bannister AJ, Morrison A, O'Carroll D, et al. Rb targets histone H3 methylation and HP1 to promoters. Nature 2001;412:561-5.
9. Dialynas GK, Vitalini MW, Wallrath LL. LinkingHeterochromatin Protein 1 (HP1) to cancer progression. Mutat Res 2008;647:13-20.
10. Itsumi M, Shiota M, Yokomizo A, Kashiwagi E, Takeuchi A, Tatsugami K, et al. Human heterochromatin protein 1 isoforms regulate androgen receptor signaling in prostate cancer. J Mol Endocrinol 2013;50:401-9.
11. Takanashi M, Oikawa K, Fujita K, Kudo M, Kinoshita M, Kuroda M. Heterochromatin protein 1gamma epigenetically regulates cell differentiation and exhibits potential as a therapeutic target for various types of cancers. Am J Pathol 2009;174:309-16.
12. De Koning L, Savignoni A, Boumendil C, Rehman H, Asselain B, Sastre- Garau X, et al. Heterochromatin protein 1alpha: A hallmark of cell proliferation relevant to clinical oncology. EMBO Mol Med 2009; 1:178-91.
13. Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell 2009;136:215-33.
14. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 2014;20:460-9.
15. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
16. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNAexpression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61.
17. Gartel AL, Radhakrishnan SK. Lost in transcription: P21 repression, mechanisms, and consequences. Cancer Res 2005;65:3980-5.
18. Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res 2001;61:6234-8.
19. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987;8:138-40.
20. Kuniyasu H, Luo Y, Fujii K, Sasahira T, Moriwaka Y, Tatsumoto N, et al. CD10 enhances metastasis of colorectal cancer by abrogating the antitumoural effect of methionine-enkephalin in the liver. Gut 2010; 59:348-56.
21. Ju J, Wang Y, Liu R, Zhang Y, Xu Z, Wu Y, et al. Human fetal globin gene expression is regulated by LYAR. Nucleic Acids Res 2014;42:9740-52.
22. Zhao Q, Rank G, Tan YT, Li H, Moritz RL, Simpson RJ, et al. PRMT5- mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat Struct Mol Biol 2009; 16:304-11.
23. Rank G, Cerruti L, Simpson RJ, Moritz RL, Jane SM, Zhao Q. Identification of a PRMT5-dependent repressor complex linked to silencing of human fetal globin gene expression. Blood 2010;116:1585-92.
24. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 2007;10:13-29.
25. van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med 2014;6:851-64.
26. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003;115:787-98.
27. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. Combinatorial microRNA target predictions. Nat Genet 2005;37:495-500.
28. James TC, Elgin SC. Identification of a nonhistone chromosomal protein associated with heterochromatin in Drosophila melanogaster and its gene. Mol Cell Biol 1986;6:3862-72.
29. Shiota M, Song Y, Yokomizo A, Tada Y, Kuroiwa K, Eto M, et al. Human heterochromatin protein 1 isoform HP1beta enhances androgen receptor activity and is implicated in prostate cancer growth. Endocr Relat Cancer 2010;17:455-67.
30. Lukasova E, Koristek Z, Falk M, Kozubek S, Grigoryev S, Kozubek M, et al. Methylation of histones in myeloid leukemias as a potential marker of granulocyte abnormalities. J Leukoc Biol 2005;77:100-11.
31. Popova EY, Claxton DF, Lukasova E, Bird PI, Grigoryev SA. Epigenetic heterochromatin markers distinguish terminally differentiated leukocytes from incompletely differentiated leukemia cells in human blood. Exp Hematol 2006;34:453-62.
32. Ruginis T, Taglia L, Matusiak D, Lee BS, Benya RV. Consequence of gastrinreleasing peptide receptor activation in a human colon cancer cell line: A proteomic approach. J Proteome Res 2006;5:1460-8.
33. Yi SA, Ryu HW, Lee DH, Han JW, Kwon SH. HP1beta suppresses metastasis of human cancer cells by decreasing the expression and activation of MMP2. Int J Oncol 2014;45:2541-8.
34. Berglund P, Landberg G. Cyclin e overexpression reduces infiltrative growth in breast cancer: yet another link between proliferation control and tumor invasion. Cell Cycle 2006;5:606-9.
35. Hall IM, Shankaranarayana GD, Noma K, Ayoub N, Cohen A, Grewal SI. Establishment and maintenance of a heterochromatin domain. Science 2002;297:2232-7.
36. Wang C, Hou X, Mohapatra S, Ma Y, Cress WD, Pledger WJ, et al. Activation of p27Kip1 Expression by E2F1. A negative feedback mechanism. J Biol Chem 2005;280:12339-43.
37. Wang C, Rauscher FJ III, Cress WD, Chen J. Regulation of E2F1 function by the nuclear corepressor KAP1. J Biol Chem 2007;282:29902-9.
38. Baraniskin A, Birkenkamp-Demtroder K, Maghnouj A, Zollner H, Munding J, Klein-Scory S, et al. MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. Carcinogenesis 2012;33:732-9.
39. Zaragosi LE, Wdziekonski B, Brigand KL, Villageois P, Mari B, Waldmann R, et al. Small RNA sequencing reveals miR-642a-3p as a novel adipocytespecific microRNA and miR-30 as a key regulator of human adipogenesis. Genome Biol 2011;12:R64.
40. Zhang Y, Matsushita N, Eigler T, Marban E. Targeted microRNA interference promotes postnatal cardiac cell-cycle re-entry. J Regen Med 2013;2:2.
41. Rogler CE, Levoci L, Ader T, Massimi A, Tchaikovskaya T, Norel R, et al. MicroRNA-23b cluster microRNAs regulate transforming growth factorbeta/bone morphogenetic protein signaling and liver stem cell differentiation by targeting Smads. Hepatology 2009;50:575-84.
42. Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J, et al.MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer 2012;130:2044-53.